Anixa Biosciences (ANIX) Operating Income (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Operating Income came in at -$2.6 million in Q2 2026, up 11.85% YoY from -$2.4 million in Q2 2025, and up 7.96% on a QoQ basis from -$2.9 million in Q4 2025.
Anixa Biosciences (ANIX) Operating Income (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Operating Income data on file, last reported at -$2.6 million in Q2 2026.
- Quarterly Operating Income rose 11.85% year-over-year to -$2.6 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$11.0 million (up 16.6% YoY) and the FY2025 annual result came in at -$11.7 million, up 15.4% from the prior year.
- Operating Income improved to -$2.6 million in Q2 2026, from -$2.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.4 million in Q3 2025 to a low of -$3.9 million in Q1 2022.
- A 5-year average of -$3.1 million and a median of -$3.1 million in 2023 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 36.26% in 2022, down 73.76% in 2022.
- Tracing ANIX's Operating Income over 5 years: stood at -$3.6 million in 2022, then gained by 15.46% to -$3.1 million in 2023, then fell by 3.67% to -$3.2 million in 2024, then climbed by 9.07% to -$2.9 million in 2025, then increased by 7.96% to -$2.6 million in 2026.
- The last three Operating Income figures came in at -$2.6 million (Q2 2026), -$2.9 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | Anixa Biosciences | 124.96 Mn | 124.96 Mn | - | -2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.65 Mn |
| Oct 31, 2025 | -2.88 Mn |
| Jul 31, 2025 | -2.44 Mn |
| Apr 30, 2025 | -3.00 Mn |
| Jan 31, 2025 | -3.39 Mn |
| Oct 31, 2024 | -3.16 Mn |
| Jul 31, 2024 | -3.59 Mn |
| Apr 30, 2024 | -3.47 Mn |
| Jan 31, 2024 | -3.61 Mn |
| Oct 31, 2023 | -3.05 Mn |
| Jul 31, 2023 | -2.84 Mn |
| Apr 30, 2023 | -2.56 Mn |
| Jan 31, 2023 | -2.56 Mn |
| Oct 31, 2022 | -3.61 Mn |
| Jul 31, 2022 | -2.80 Mn |
| Apr 30, 2022 | -3.59 Mn |
| Jan 31, 2022 | -3.88 Mn |
| Oct 31, 2021 | -4.08 Mn |
| Jul 31, 2021 | -4.39 Mn |
| Apr 30, 2021 | -2.44 Mn |